



## **Antengene to Participate in the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference and Deliver a Presentation**

Shanghai and Hong Kong, PRC, January 8, 2026 — Antengene Corporation Limited ( **“Antengene”** , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that **Dr. Jay Mei, Antengene’s Founder, Chairman and CEO, together with the company’s senior management team, will attend the 44<sup>th</sup> J.P. Morgan Healthcare Conference, to be held from January 12<sup>th</sup> to 15<sup>th</sup>, 2026, in San Francisco, California, USA. Dr. Mei will deliver a company presentation on January 15<sup>th</sup>.**



### **Details of the Presentation**

**Title:** Treating Patients Beyond Borders – Antengene Pipeline Overview

**Speaker:** Dr. Jay Mei, Antengene’s Founder, Chairman and CEO

**Date:** Thursday, January 15th, 2026

**Time:** 8:30 AM – 8:55 AM, Pacific Time (including a brief Q&A session)

**Venue:** 32nd Floor, The Westin St. Francis San Francisco

During the presentation, Dr. Mei will share the latest updates on Antengene’s pipeline, including updated clinical data for ATG-022 (CLDN18.2 ADC).



Compared with data previously presented at the Company's R&D Day in November 2025, the updated results demonstrate an **improved objective response rate (ORR) and longer median progression-free survival (mPFS), while continuing to show a low incidence of Grade 3 or higher treatment-related adverse events (TRAEs)** in the 1.8 mg/kg cohort of patients with CLDN18.2+ (2+ ≥20%) gastric cancer.

The presentation will also highlight Antengene's strategic focus on **antibody-drug conjugates (ADCs) integrated with immuno-oncology (IO)**, featuring ATG-125 (B7-H3 × PD-L1 ADC), as well as the Company's **next-generation T-cell engagers developed using its proprietary AnTenGager™ platform**, with potential applications across oncology and autoimmune diseases.

### **One-on-one Meetings**

**Date:** January 12<sup>th</sup> to 15<sup>th</sup>, 2026

Antengene's management team will be available for one-on-one meetings during the conference. **Interested parties are welcome to contact J.P. Morgan or Antengene's Business Development / Investor Relations team to arrange a meeting.** We look forward to engaging in insightful discussions and exploring new partnerships across the healthcare sector to accelerate innovation and industry growth.

### **About Antengene**

Antengene Corporation Limited ( "**Antengene**" , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody),



ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

### **Forward-looking statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further



discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.